ADAP250117C7500
- 0.00
- 0.000.00%
Adaptimmune Therapeutics Newsroom
European Equities Traded in the US as American Depositary Move Slightly Lower in Thursday Trading
Adaptimmune Says CFO, Other C-Suite Officer to Step Down
Adaptimmune: Focusing Increasing Proportion of Corporate Functions in U.S. >ADAP
Adaptimmune: Co-Founder, Chief Business & Strategy Officer Helen Tayton-Martin to Step Down on March 31 >ADAP
Express News | Adaptimmune Therapeutics PLC - Gavin Wood to Step Down as Chief Financial Officer
First Patient Treated With Adaptimmune's TECELRA(R) (Afamitresgene Autoleucel)
Express News | Mizuho Maintains Outperform on Adaptimmune Therapeutics, Lowers Price Target to $1.5
Mizuho Securities Maintains Adaptimmune Therapeutics(ADAP.US) With Buy Rating
Adaptimmune Therapeutics Analyst Ratings
European Equities Traded in the US as American Depositary Decline Slightly in Tuesday Trading
H.C. Wainwright Maintains Adaptimmune Therapeutics(ADAP.US) With Buy Rating, Maintains Target Price $3.5
Promising Future for Adaptimmune Therapeutics: Buy Rating Supported by Breakthrough Therapies and Strong Financial Position
Analysts' Opinions Are Mixed on These Healthcare Stocks: Adaptimmune Therapeutics (ADAP), Fulcrum Therapeutics (FULC) and Immunic (IMUX)
Adaptimmune Therapeutics Third Quarter 2024 Earnings: Beats Expectations
Adaptimmune Therapeutics Is Maintained at Buy by Guggenheim
Express News | Adaptimmune Therapeutics PLC : Guggenheim Cuts Target Price to $3 From $4
Shareholders in Adaptimmune Therapeutics (NASDAQ:ADAP) Have Lost 86%, as Stock Drops 26% This Past Week
Wells Fargo Maintains Adaptimmune Therapeutics(ADAP.US) With Hold Rating, Maintains Target Price $2
Adaptimmune Therapeutics Shares Are Trading Lower. The Company Reported Q3 Financial Results.
Express News | Adaptimmune Therapeutics Shares Are Trading Lower. The Company Reported Q3 Financial Results